New oral drug shows promise in reducing blood transfusions for genetic blood disorders
NCT ID NCT04987489
Summary
This Phase 2 clinical trial tested an oral medication called etavopivat in 53 patients with sickle cell disease or thalassemia. The study aimed to see if the drug could safely reduce patients' need for blood transfusions and increase their hemoglobin levels. Researchers measured whether patients could achieve at least a 20% reduction in transfusions or a meaningful increase in hemoglobin over 12 weeks of treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SICKLE CELL DISEASE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
A.O.U. Università Studi della Campania "Luigi Vanvitelli"
Naples, 80138, Italy
-
AORN A. Cardarelli
Naples, 80131, Italy
-
Abu El-Reesh El-Mounira Children University Hospital
Cairo, Egypt, 4241317, Egypt
-
Barts Health NHS Trust - The Royal London Hospital
London, E1 1FR, United Kingdom
-
CHU Sainte-Justine Mother and Child University Hospital
Montreal, Quebec, H3T 1C5, Canada
-
Cairo University
Cairo, 12613, Egypt
-
Children's Hospital of Atlanta
Atlanta, Georgia, 30342, United States
-
Children's Hosptl Philadelphia
Philadelphia, Pennsylvania, 19104, United States
-
Children's National Health Hospital
Washington D.C., District of Columbia, 20010, United States
-
Chronic Care Center
Baabda, RGWX 4CG, Lebanon
-
Duke University
Durham, North Carolina, 27710, United States
-
East Carolina University
Greenville, North Carolina, 27858, United States
-
Fondazione IRCSS Ca' Granda Ospedale Maggiore Policlinico
Milan, 20122, Italy
-
Galliera Hospital Centro Anemie Congenite
Genova, 16128, Italy
-
Hammersmith Hospital - London
London, W12 0HS, United Kingdom
-
Hospital Nini
Tripoli, 1434, Lebanon
-
Kings College London
London, SE5 9RS, United Kingdom
-
Manchester University NHS Foundation Trust
Manchester, M13 9WL, United Kingdom
-
Master Centre for Canada
Mississauga, Ontario, L4W 4XI, Canada
-
Sandwell and West Birmingham NHS Trust SCAT/ haematology
Birmingham, B18 7QH, United Kingdom
-
TOI Clinical Research
Cerritos, California, 90703, United States
-
The Hospital for Sick Children
Toronto, Ontario, M5G 1X8, Canada
-
UCI Health
Orange, California, 92868, United States
-
UCSF Oakland Benioff ChildHosp
Oakland, California, 94609, United States
-
University College Hospital - University College London Hospitals NHS Foundation Trust
London, NW1 2PG, United Kingdom
-
University Health Network - Toronto General Hospital
Toronto, Ontario, M5G 2C4, Canada
-
University of Californ LA-UCLA
Los Angeles, California, 90095, United States
-
Weill Medical College of Cornell University
New York, New York, 10065, United States
-
[Legal] Children's Hospital Los Angeles
Los Angeles, California, 90027, United States
-
[Legal] Children's Hospital Medical Center dba Cincinnati Children's
Cincinnati, Ohio, 45229, United States
-
[Legal] Children's Hospital of Orange County on behalf of CHOC Children's Hospital of Orange County
Orange, California, 92868, United States
-
[Legal] Dr. Vince Clinical Research, LLC and Dr. Vince Clinical Research, P.A.
Detroit, Michigan, 48201-2018, United States
Conditions
Explore the condition pages connected to this study.